Breakthrough in Cancer Treatment: FDA Approves Enhertu for HER2-Positive Solid Tumors

In July 2024, the FDA granted accelerated approval for Enhertu (trastuzumab deruxtecan or T-DXd) to treat any HER2-positive solid tumor. This innovative therapy has shown remarkable efficacy in clinical trials, especially for gynecologic cancers like endometrial and cervical cancers, as well as rare cancers such as salivary gland and biliary tract cancers. With significant response rates and durable outcomes, Enhertu offers a new beacon of hope for patients with hard-to-treat cancers. However, careful monitoring for side effects like interstitial lung disease (ILD) is crucial.